Blog

LONDON, Oct 10 (Reuters) – The Gates Foundation and the Pan American Health Organization are both working on ways to make weight-loss drugs like Novo Nordisk’s Wegovy and Eli Lilly’s Mounjaro more accessible in lower-income countries, the global health groups told Reuters.

In separate interviews, Microsoft founder Bill Gates and PAHO director Dr Jarbas Barbosa said for the first time that their organizations were each seeking strategies to remedy the unequal availability of the highly effective but expensive treatments.

Sign up here.

In response to a question about the treatments, Gates said his Foundation would take any drug that was effective in high-income countries “and figure out how to make it super, super cheap so that it can get to everyone in the world”.

LOW-COST COPIES

The brand-name weight-loss drugs are primarily sold in wealthier countries, where prescriptions cost hundreds of dollars per month.

The Gates Foundation could also potentially support clinical trials to test how these medicines affect different populations and provide the data needed to broaden access, Gates said.

Obesity’s role in chronic illness has created a new urgency around addressing rising global rates, although it is still not the biggest problem facing most of the countries where the Foundation operates, Gates said.

The World Health Organization estimates that the economic costs of overweight and obesity will reach $3 trillion by 2030 if nothing is done to contain it.

Its Americas arm, PAHO, manages a fund that helps push down medicine prices by guaranteeing bulk orders on behalf of its 35 member states.

Using the fund, which is financed by the member states, is an option for weight-loss drugs, Barbosa told Reuters. He said it could also help manufacturers clear regulatory requirements rather than applying in each country for approval.

“We are starting the conversation,” he said, adding that PAHO is developing recommendations for how best to use the drugs and plans to speak to Novo, Lilly and generic drugmakers within the next couple of weeks.

“We are deeply committed to serving patients around the world,” the Danish company said.

Our Standards: The Thomson Reuters Trust Principles., opens new tab